Skip Navigation LinksHome > August 2014 - Volume 62 - Issue 6 > Autoantibodies to C-Reactive Protein in Incomplete Lupus and...
Journal of Investigative Medicine:
doi: 10.1097/JIM.0000000000000094
Brief Report

Autoantibodies to C-Reactive Protein in Incomplete Lupus and Systemic Lupus Erythematosus

Jung, Ju-Yang MD; Koh, Bo-Ram MD; Kim, Hyoun-Ah MD; Jeon, Ja-Young PhD; Suh, Chang-Hee MD, PhD

Collapse Box


Objective: Anti-C-reactive protein (CRP) antibodies have been described in patients with systemic lupus erythematosus (SLE). We investigated the potential of the anti-CRP antibody as a marker for disease activity in SLE patients and as a predictor of progression to SLE in patients with incomplete lupus.

Methods: Immunoglobulin G anti-CRP antibody levels were measured using an enzyme-linked immunosorbent assay.

Results: Patients with incomplete lupus exhibited clinical and immunologic characteristics different from those in SLE patients: no serositis and alopecia, more common oral ulcers and arthritis, lower disease activity index, lower positivity for antinuclear and anti–double-strand DNA antibodies, and higher complement levels. Anti-CRP antibody levels were higher in SLE patients (35.6 [35.1] AU) than in patients with incomplete lupus (23.1 [25.8] AU, P = 0.016) and normal controls (21.0 [14.3] AU, P < 0.001). Anti-CRP antibody was significantly higher in SLE patients with arthritis and correlated with disease activity markers, including antichromatin antibody. However, no difference in anti-CRP antibody levels was observed between patients with incomplete lupus that progressed to SLE and those whose did not.

Conclusion: These data suggest that anti-CRP antibodies can neither be used as biomarkers in SLE nor predict SLE progression in patients with incomplete lupus.

Copyright © 2014 by the American Federation for Medical Research.


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.